Wardynski & Partners has advised CNS Pharmaceuticals on negotiating a contract to supply Berubicin to the Pomeranian Medical University.
“Berubicin is a medicinal substance being studied for use in oncology, in particular for the treatment of the brain glioblastoma multiforme, as well as other conditions such as central nervous system lymphomas,” Wardynski & Partners informed. “The project will be implemented in the form of a non-commercial clinical trial financed by the Polish Medical Research Agency.”
CNS Pharmaceuticals is a US-based biotechnology company that is researching the use of Berubicin for the treatment of aggressive brain cancers and the development of oncology therapies.
Established in 1948, the Pomeranian Medical University in Szczecin includes the Medicine, Dentistry, Biotechnology, and Health Sciences faculties. According to the firm, it is one of the leading oncology centers in Poland.
The Wardynski & Partners team included Partners Izabela Zielinska-Barlozek, Anna Prigan, Monika Gorska, and Joanna Prokurat, Counsel Joanna Krakowiak, Attorney-at-Law Jakub Macek, and Lawyer Oliwia Kruczynska.